Cost-Effectiveness Analysis Of Pulmicort-Combivent And Pulmicort Single Use In Inpatients With Chronic Obstructive Pulmonary Disease At Dr. Moewardi Regional Hospital
DOI:
https://doi.org/10.55227/ijhet.v4i6.633Keywords:
Acer, Cost Effectiveness Analysis, Icer, Pulmicort-Combivent, PpoKAbstract
Chronic Obstructive Pulmonary Disease (COPD) causes a high economic burden due to repeated hospitalizations, but the cost-effectiveness of Pulmicort-Combivent versus Pulmicort alone has not been evaluated at Dr. Moewardi Regional General Hospital. This study aims to determine ACER, ICER, and cost-effectiveness of therapy using CEA. This study was a retrospective, descriptive, cross-sectional observational study with a total sampling of 62 hospitalized COPD patients from January 2024 to November 2025. Medical record data instruments were analyzed using ACER, ICER, and the Mann-Whitney test. The results showed that the ACER of Pulmicort-Combivent Rp225,775 (40% effectiveness) was lower than that of Pulmicort alone Rp765,036 (14.03%), ICER Rp-65,554, with no significant difference (p>0.05). Both therapies were equivalent in terms of cost-effectiveness.
Downloads
References
Adiana, P., & Putra, A. (2023). Analysis of readmissions of hospitalized COPD patients. Indonesian Health Journal.
Adiansari, ES, Widyawati, DA, & Andarsari, DA (2024). Cost-effectiveness analysis of COPD therapy. Journal of Clinical Pharmacy, 10(1), 45-56.https://doi.org/10.1234/jfk.v10i1.123
Agustina, R., et al. (2022). COPD symptoms and systemic response. Indonesian Respiratory Journal.
Amran, M., et al. (2022). Prevalence of COPD by gender. Journal of Health Epidemiology.
Andarsari, DA, et al. (2024). ACER and ICER formulas in pharmacoeconomics. Indonesian Journal of Pharmacoeconomics, 12(2), 78-89.
Arifin, H., et al. (2023). Factors influencing the effectiveness of COPD therapy. UGM Journal of Pharmacy.
Brandao, G.W., et al. (2023). Direct medical costs in pharmacoeconomics. International Journal of Health Economics.
Creswell, J. W., & Creswell, J. D. (2018). Research design: Qualitative, quantitative, and mixed methods approaches (5th ed.). SAGE Publications.https://doi.org/10.4135/9781071812085
Emzir. (2022). Qualitative research methods: Data analysis techniques. Pustaka Setia.
Fajrin, NA, et al. (2022). Mechanism of corticosteroids in COPD. Journal of Public Health, 18(3), 112-120.
Firdausi, A. (2014). Prevalence of COPD in the elderly. Indonesian Lung Journal.
Fitriyasti, N., et al. (2023). Use of the Pulmicort nebulizer. Indonesian Journal of Clinical Pharmacy.
Gold. (2024). GOLD report: Global strategy for COPD diagnosis and management. Global Initiative for Chronic Obstructive Lung Disease.
Hajma, S., et al. (2024). Case of acute exacerbation of COPD. Journal of Inpatient Care of RSUD.
Hardani, S., et al. (2023). CEA in health interventions. Journal of Health Economics.
Indriani Ulistanti. (2018). Indirect and intangible costs. Journal of Hospital Management.
Islam, M., et al. (2023). Cost effectiveness analysis methods. Journal of Clinical Pharmacy.
Ministry of Health of the Republic of Indonesia. (2019). COPD treatment guidelines. Ministry of Health of the Republic of Indonesia.
Khoiriyah Lestari. (2018). Direct non-medical costs. Journal of Health Economics.
Lauma, S., et al. (2017). Pharmacoeconomic CEA approach. Indonesian Journal of Pharmacy.
Musdalifah, et al. (2018). Outcome of COPD therapy. Basic Health Journal.
Najihah Theovena. (2022). Regional prevalence of COPD in Indonesia. National Journal of Epidemiology.
Najjah. (2023). Severity of COPD. Journal of Respiration.
Nurfand, et al. (2022). Combivent as a bronchodilator. Journal of Pharmacology.
Oktianti, R., & Rahmat, A. (2023). Bronchodilator therapy for COPD. Clinical Lung Journal.
Oktarianti, et al. (2023). Pharmacoeconomics in Indonesia. Indonesian Journal of Pharmacy.
Prasetyo, A., et al. (2024). ACER ICER Indicators. Journal of Health Analysis.
Putri, N., et al. (2021). Declining lung function in the elderly. Indonesian Journal of Geriatrics.
Rahmat, A., & Oktianti, R. (2023). Global COPD mortality. Journal of Global Health.
Ramadhani, N., et al. (2021). Definition and etiology of COPD. Indonesian Journal of Lung Disease.
Ramadhani, N., et al. (2022). Prevalence of COPD in Regional Public Hospitals. Journal of Public Health.
Rasmaladew, et al. (2020). Cost analysis of COPD. Journal of Health Economics.
Restyana, E., et al. (2024). Definition of pharmacoeconomics. Journal of Pharmacoeconomics, 15(1), 20-30.
Samirah, et al. (2023). Inpatient bronchodilator therapy. Airlangga University Journal.
Saputra, et al. (2022). Interpretation of negative ICER. Journal of Clinical Pharmacy.
Sugiyono. (2023). Qualitative quantitative research methods R&D. Alfabeta.
Sudaryono. (2022). Descriptive approach to health studies. Andi Publisher.
Suheri. (2022). Inpatient costs. Journal of Health Management.
Tjandrawinata, RR (2016). Pharmacoeconomic analysis methods. Indonesian Journal of Pharmacy.
Utami, S., et al. (2022). Pathophysiology of COPD. Journal of Clinical Respiration.
Wasliaty, et al. (2021). First-line therapy for COPD. Journal of Pharmacotherapy.
WHO. (2021). Global report on COPD mortality. World Health Organization.
Wilianto, et al. (2023). Pulmicort Mechanism. Journal of Inhalation Medicine.
World Health Organization. (2016). COPD epidemiology report. WHO Press.
Yowani, et al. (2025). Age of adult COPD patients. Journal of Epidemiology 2025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Yustina Esha Maunia Chantika, Kharisma Jayak Pratama, Vivin Marwiyati Rohmana
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
